Warburg Pincus, a global private equity firm, has acquired JHP Pharmaceuticals for $195 million on a debt-free, cash-free basis. JHP's current management team will continue to hold an interest in the company. Additional terms of the transaction were not disclosed.
JHP is specialty pharmaceutical company focused on the U.S. sterile injectable drug market. With growth capital and support from Warburg Pincus, the company will pursue partnership and acquisition opportunities in both the branded and generic segments of the sterile injectable market.
“Over the past five years, JHP has established itself as a strong injectable pharmaceutical business manufacturing and marketing its own branded and generic products, developing a strong generic products pipeline, and supporting other pharmaceutical companies in the development and manufacturing of innovative products,” said Stuart Hinchen, co-founder and chief executive officer of JHP. “We believe Warburg Pincus is an ideal partner for JHP's growth and expansion in the coming years.”
"We have been impressed with the financial performance and quality record of JHP over the last five years, and are very pleased to contribute to the further development of the company," said Elizabeth H Weatherman, managing director and head of Warburg Pincus’ Healthcare Group,. "The management team has done an excellent job building the company and we are delighted they are remaining with the business and co-investing. JHP represents an attractive investment opportunity for us and we have reserved a sizeable amount of additional capital to fund growth opportunities that will transform the business well beyond what it is today.”